Strategies to combat Tay-Sachs disease - ScienceDirect

Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo: Molecular Therapy - Methods & Clinical Development

Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment - Genetics in Medicine

PDF) An Inducible Mouse Model of Late Onset Tay–Sachs Disease

group_5_presentation_2_-_tay-sachs_disease - Wiki

Reassessing neurodegenerative disease: immune protection pathways and antagonistic pleiotropy: Trends in Neurosciences

Mutation Story – Tay-Sachs

Sphingolipid metabolism diseases - ScienceDirect

Natural history of Tay-Sachs disease in sheep - ScienceDirect

Frontiers Therapeutic Strategies For Tay-Sachs Disease

Infantile gangliosidoses: Mapping a timeline of clinical changes - ScienceDirect

How Common Is Tay-Sachs Disease?

Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis - The Lancet Neurology

Beta N Acetylhexosaminidase A - an overview

The misuse of race in the search for disease-causing alleles - The Lancet

Tay Sachs disease carrier screening in schools: Educational alternatives and cheekbrush sampling